Douglas C Dean1, Samuel A Hurley2, Steven R Kecskemeti1, J Patrick O'Grady3, Cristybelle Canda3, Nancy J Davenport-Sis4, Cynthia M Carlsson5, Henrik Zetterberg6, Kaj Blennow7, Sanjay Asthana8, Mark A Sager4, Sterling C Johnson8, Andrew L Alexander9, Barbara B Bendlin5. 1. Waisman Center, University of Wisconsin-Madison. 2. Oxford Centre for Functional Magnetic Resonance Imaging of the Brain, University of Oxford, Oxford, England. 3. Alzheimer Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison. 4. Alzheimer Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer Institute, University of Wisconsin School of Medicine and Public Health, Madison. 5. Alzheimer Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison5Geriatric Research Education and Clinical Center, William S. Middleton Memorial VA Hospital, Madison, Wisconsin. 6. Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden7Department of Molecular Neuroscience, Institute of Neurology, University College London, London, England. 7. Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden. 8. Alzheimer Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison4Wisconsin Alzheimer Institute, University of Wisconsin School of Medicine and Public Health, Madison5Geriatric Research Education and Clinical Center, William S. Middleton Memorial VA Hospital, Madison, Wisconsin. 9. Waisman Center, University of Wisconsin-Madison8Department of Medical Physics, University of Wisconsin School of Medicine and Public Health, Madison9Department of Psychiatry, University of Wisconsin School of Medicine and Public Health, Madison.
Abstract
IMPORTANCE: The accumulation of aggregated β-amyloid and tau proteins into plaques and tangles is a central feature of Alzheimer disease (AD). While plaque and tangle accumulation likely contributes to neuron and synapse loss, disease-related changes to oligodendrocytes and myelin are also suspected of playing a role in development of AD dementia. Still, to our knowledge, little is known about AD-related myelin changes, and even when present, they are often regarded as secondary to concomitant arteriosclerosis or related to aging. OBJECTIVE: To assess associations between hallmark AD pathology and novel quantitative neuroimaging markers while being sensitive to white matter myelin content. DESIGN, SETTING, AND PARTICIPANTS: Magnetic resonance imaging was performed at an academic research neuroimaging center on a cohort of 71 cognitively asymptomatic adults enriched for AD risk. Lumbar punctures were performed and assayed for cerebrospinal fluid (CSF) biomarkers of AD pathology, including β-amyloid 42, total tau protein, phosphorylated tau 181, and soluble amyloid precursor protein. We measured whole-brain longitudinal and transverse relaxation rates as well as the myelin water fraction from each of these individuals. MAIN OUTCOMES AND MEASURES: Automated brain mapping algorithms and statistical models were used to evaluate the relationships between age, CSF biomarkers of AD pathology, and quantitative magnetic resonance imaging relaxometry measures, including the longitudinal and transverse relaxation rates and the myelin water fraction. RESULTS: The mean (SD) age for the 19 male participants and 52 female participants in the study was 61.6 (6.4) years. Widespread age-related changes to myelin were observed across the brain, particularly in late myelinating brain regions such as frontal white matter and the genu of the corpus callosum. Quantitative relaxometry measures were negatively associated with levels of CSF biomarkers across brain white matter and in areas preferentially affected in AD. Furthermore, significant age-by-biomarker interactions were observed between myelin water fraction and phosphorylated tau 181/β-amyloid 42, suggesting that phosphorylated tau 181/β-amyloid 42 levels modulate age-related changes in myelin water fraction. CONCLUSIONS AND RELEVANCE: These findings suggest amyloid pathologies significantly influence white matter and that these abnormalities may signify an early feature of the disease process. We expect that clarifying the nature of myelin damage in preclinical AD may be informative on the disease's course and lead to new markers of efficacy for prevention and treatment trials.
IMPORTANCE: The accumulation of aggregated β-amyloid and tau proteins into plaques and tangles is a central feature of Alzheimer disease (AD). While plaque and tangle accumulation likely contributes to neuron and synapse loss, disease-related changes to oligodendrocytes and myelin are also suspected of playing a role in development of AD dementia. Still, to our knowledge, little is known about AD-related myelin changes, and even when present, they are often regarded as secondary to concomitant arteriosclerosis or related to aging. OBJECTIVE: To assess associations between hallmark AD pathology and novel quantitative neuroimaging markers while being sensitive to white matter myelin content. DESIGN, SETTING, AND PARTICIPANTS: Magnetic resonance imaging was performed at an academic research neuroimaging center on a cohort of 71 cognitively asymptomatic adults enriched for AD risk. Lumbar punctures were performed and assayed for cerebrospinal fluid (CSF) biomarkers of AD pathology, including β-amyloid 42, total tau protein, phosphorylated tau 181, and soluble amyloid precursor protein. We measured whole-brain longitudinal and transverse relaxation rates as well as the myelin water fraction from each of these individuals. MAIN OUTCOMES AND MEASURES: Automated brain mapping algorithms and statistical models were used to evaluate the relationships between age, CSF biomarkers of AD pathology, and quantitative magnetic resonance imaging relaxometry measures, including the longitudinal and transverse relaxation rates and the myelin water fraction. RESULTS: The mean (SD) age for the 19 male participants and 52 female participants in the study was 61.6 (6.4) years. Widespread age-related changes to myelin were observed across the brain, particularly in late myelinating brain regions such as frontal white matter and the genu of the corpus callosum. Quantitative relaxometry measures were negatively associated with levels of CSF biomarkers across brain white matter and in areas preferentially affected in AD. Furthermore, significant age-by-biomarker interactions were observed between myelin water fraction and phosphorylated tau 181/β-amyloid 42, suggesting that phosphorylated tau 181/β-amyloid 42 levels modulate age-related changes in myelin water fraction. CONCLUSIONS AND RELEVANCE: These findings suggest amyloid pathologies significantly influence white matter and that these abnormalities may signify an early feature of the disease process. We expect that clarifying the nature of myelin damage in preclinical AD may be informative on the disease's course and lead to new markers of efficacy for prevention and treatment trials.
Authors: J N Giedd; J Blumenthal; N O Jeffries; F X Castellanos; H Liu; A Zijdenbos; T Paus; A C Evans; J L Rapoport Journal: Nat Neurosci Date: 1999-10 Impact factor: 24.884
Authors: Maya K Desai; Kelly L Sudol; Michelle C Janelsins; Michael A Mastrangelo; Maria E Frazer; William J Bowers Journal: Glia Date: 2009-01-01 Impact factor: 7.452
Authors: Thaddeus J Haight; Susan M Landau; Owen Carmichael; Christopher Schwarz; Charles DeCarli; William J Jagust Journal: JAMA Neurol Date: 2013-08 Impact factor: 18.302
Authors: Douglas C Dean; Jonathan O'Muircheartaigh; Holly Dirks; Nicole Waskiewicz; Lindsay Walker; Ellen Doernberg; Irene Piryatinsky; Sean C L Deoni Journal: Brain Struct Funct Date: 2014-04-08 Impact factor: 3.270
Authors: Sean C L Deoni; Douglas C Dean; Jonathan O'Muircheartaigh; Holly Dirks; Beth A Jerskey Journal: Neuroimage Date: 2012-08-02 Impact factor: 6.556
Authors: Christine L Tardif; Gabriel A Devenyi; Robert S C Amaral; Sandra Pelleieux; Judes Poirier; Pedro Rosa-Neto; John Breitner; M Mallar Chakravarty Journal: Hum Brain Mapp Date: 2017-11-21 Impact factor: 5.038
Authors: Mariet Allen; Xue Wang; Jeremy D Burgess; Jens Watzlawik; Daniel J Serie; Curtis S Younkin; Thuy Nguyen; Kimberly G Malphrus; Sarah Lincoln; Minerva M Carrasquillo; Charlotte Ho; Paramita Chakrabarty; Samantha Strickland; Melissa E Murray; Vivek Swarup; Daniel H Geschwind; Nicholas T Seyfried; Eric B Dammer; James J Lah; Allan I Levey; Todd E Golde; Cory Funk; Hongdong Li; Nathan D Price; Ronald C Petersen; Neill R Graff-Radford; Steven G Younkin; Dennis W Dickson; Julia R Crook; Yan W Asmann; Nilüfer Ertekin-Taner Journal: Alzheimers Dement Date: 2017-10-31 Impact factor: 21.566
Authors: Andreana Benitez; Jens H Jensen; Maria Fatima Falangola; Paul J Nietert; Joseph A Helpern Journal: Neurobiol Aging Date: 2018-07-17 Impact factor: 4.673
Authors: Mustapha Bouhrara; David A Reiter; Christopher M Bergeron; Linda M Zukley; Luigi Ferrucci; Susan M Resnick; Richard G Spencer Journal: Alzheimers Dement Date: 2018-04-19 Impact factor: 21.566
Authors: Mustapha Bouhrara; Abinand C Rejimon; Luis E Cortina; Nikkita Khattar; Christopher M Bergeron; Luigi Ferrucci; Susan M Resnick; Richard G Spencer Journal: Neurobiol Aging Date: 2019-10-14 Impact factor: 4.673
Authors: Mustapha Bouhrara; Abinand C Rejimon; Luis E Cortina; Nikkita Khattar; Richard G Spencer Journal: Magn Reson Imaging Date: 2019-11-12 Impact factor: 2.546